Isaac Esseesse, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 107 Longwood Ave, Rockledge, FL 32955 Phone: 321-636-2111 Fax: 321-636-9219 |
Carl Tahn, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 107 Longwood Ave, Rockledge, FL 32955 Phone: 321-636-2111 Fax: 321-636-7180 |
Giuseppe Palermo, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 107 Longwood Ave, Rockledge, FL 32955 Phone: 321-636-2111 Fax: 321-636-9219 |
News Archive
Cancer diagnostics and treatment options could be drastically improved with the creation of a 'designer' nanodevice being developed by researchers from the UK, Italy, the US and Argentina.
Since the emergence in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide via transmission among close human contacts. Early on, several public health interventions were implemented in Wuhan city and Hubei Province, including lockdowns, social distancing, traffic restrictions, stay-at-home policies, face mask requirements, building temporary hospitals, and centralized quarantine. There were 50,355 confirmed cases of SARS-CoV-2 infection in Wuhan as of 28 January 2021.
Finding innovative, minimally invasive ways to treat liver cancer-and being able to tailor that treatment individually to patients-are hallmarks of interventional radiologists. Advances in yttrium-90 (Y-90) radioembolization for liver cancer, a leading cause of cancer deaths worldwide, are reported in studies in the October Journal of Vascular and Interventional Radiology.
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
Gov. Mark Dayton had to disappoint some of his strongest political supporters to come up with the deal Thursday that will end Minnesota's government shutdown. ... But Dayton did extract things from Republicans that they hadn't been willing to yield at shutdown time. The Republican "policy issues" that run throughout the Republican budget bills will disappear.
› Verified 4 days ago